Marksans Pharma UK subsidiary secures new product authorizations

Marksans Pharma Limited announced on September 23, 2025, that its wholly-owned UK subsidiary, Relonchem Limited, has received marketing authorizations from the UK MHRA for two new products: Moxonidine 200 microgram Tablets and Moxonidine 400 microgram Tablets. This development enhances the company's offering in the European market.

Marksans Pharma, headquartered in Mumbai, India, researches, manufactures, and markets generic pharmaceutical formulations globally. Its manufacturing facilities in India, USA, and UK are approved by major regulatory agencies, including USFDA, UK MHRA, and Australian TGA.

The company’s product portfolio covers therapeutic segments such as CVS, CNS, anti-diabetic, pain management, gastroenterological, and anti-allergies, which it markets internationally.